Full Program Just Released!
Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Andrew Kyle

Andrew Kyle

Associate Director, Process R&D SK pharmateco

Seminars

Tuesday 13th October 2026

Streamlining Internal & Outsourced ADC CMC Strategy to Efficiently Manufacture Cost-Effective ADCs at Scale

Andrew Kyle - Speaker at 17th World ADC San Diego Summit

View all Speakers

View Event Brochure